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Plant-expressed cocaine hydrolase
variants of butyrylcholinesterase
exhibit altered allosteric effects
of cholinesterase activity and
increased inhibitor sensitivity
Katherine E. Larrimore1,5, I. Can Kazan2, Latha Kannan1, R. Player Kendle1,6, Tameem Jamal1,
Matthew Barcus1,7, Ashini Bolia2,8, Stephen Brimijoin3, Chang-Guo Zhan4, S. Banu Ozkan2 &
Tsafrir S. Mor 1
Butyrylcholinesterase (BChE) is an enzyme with broad substrate and ligand specificities and may
function as a generalized bioscavenger by binding and/or hydrolyzing various xenobiotic agents and
toxicants, many of which target the central and peripheral nervous systems. Variants of BChE were
rationally designed to increase the enzyme’s ability to hydrolyze the psychoactive enantiomer of
cocaine. These variants were cloned, and then expressed using the magnICON transient expression
system in plants and their enzymatic properties were investigated. In particular, we explored the effects
that these site-directed mutations have over the enzyme kinetics with various substrates of BChE. We
further compared the affinity of various anticholinesterases including organophosphorous nerve agents
and pesticides toward these BChE variants relative to the wild type enzyme. In addition to serving as a
therapy for cocaine addiction-related diseases, enhanced bioscavenging against other harmful agents
could add to the practicality and versatility of the plant-derived recombinant enzyme as a multivalent
therapeutic.
The human serum enzyme butyrylcholinesterase (BChE) is a promiscuous enzyme capable of binding and/
or hydrolyzing a diverse array of compounds including many natural and man-made toxicants of the central
and peripheral nervous system, unlike the highly-selective, homologous enzyme, acetylcholinesterase (AChE)1.
BChE is capable of counteracting the toxicity of various anticholinesterases by binding to them before they reach
their targets in the nervous system. BChE is capable of detoxifying organophosphorous (OP) nerve agents like
paraoxon, as well as acetylcholine receptor antagonists, and psychoactive plant alkaloids such as cocaine2–5.
Exogenously-supplied BChE can augment the bioscavenging capacity of the endogenous enzyme and provide
broad protection by sequestering the anticholinesterase agents6–9. Moreover, recombinantly-produced BChE variants with improved binding affinities and catalytic prowess can be created to improve on the parameters of the
wild type (WT) enzyme.
In addition to improving BChE’s binding affinity toward anticholinesterase agents, the hydrolytic activity
of human BChE (hBChE) against cocaine has also been a target for improvement. The catalytic activity of WT
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hBChE against cocaine is measurable, albeit slow, and provides one of the major detoxification pathways for the
drug, generating non-psychoactive metabolites10, 11. Mutants of BChE have been rationally-designed, creating
highly efficient recombinant cocaine hydrolases aimed toward an enzyme-based therapy to treat drug overdose
and addiction12–19. When designing BChE-based cocaine hydrolase mutants, care was taken to ensure that their
ability to hydrolyze the crucially important substrate, acetylcholine (ACh), was not significantly enhanced.
A low-cost, sustainable, source of recombinant BChE must be readily available to produce clinically useful
quantities of BChE mutants. Rapid and high level transient expression of foreign proteins in plants is needed
to efficiently screen copious numbers of mutant variants, while maintaining the ability to ramp up production
greatly when mutants of particular interest have been established. Mammalian expression systems have been used
to produce cocaine hydrolase variants of BChE20, but such platforms can be difficult and expensive to scale up21.
Plant-based recombinant protein production systems, in particular transient expression systems that make use of
viral vectors (Fig. 1a), have advantages including reduced production costs, similar or cheaper downstream costs,
as well as easy scalability5, 22, 23.
Our lab has previously shown that the tobacco relative Nicotiana benthamiana can serve as a source
for clinically-relevant quantities of cocaine hydrolase variants of BChE 24, 25 . These highly efficient
cocaine-metabolizing variants of BChE were designed with the goal of increasing catalytic efficiency of cocaine
hydrolysis toward an anti-cocaine treatment. But how the newly introduced mutations affect the enzymes’ sensitivity to anticholinesterases and its kinetics with choline ester substrates remains unknown.
Here we report the complex kinetic behavior of the plant-derived cocaine hydrolase variants of BChE (pBChE)
and their enhanced anticholinesterase scavenging ability. Using Dynamic Coupling Index (DCI) analysis we have
evidence that the mutations allosterically affect the catalytic triad not only within a single subunit, but also propagate to neighboring subunits of the BChE oligomer.

Results and Discussion

Plant production of a recombinant cocaine-hydrolyzing human BChE variant. Several research
groups have been working on rational re-design of BChE into a cocaine hydrolase13, 15, 19, 26, 27. The group led by
Zhan used hybrid quantum mechanical/molecular mechanical (QM/MM) method-based predictions followed
by validation through in vitro and in vivo experiments. This process provided evidence for a correlation between
the measured catalytic efficiency of cocaine hydrolysis and the sum of the enzyme-substrate hydrogen-bonding
distances within the first transition state. In successive papers Zhan et al. reported the further design of BChE
variants with ever increasing catalytic efficiency15–18, 28–32.
We previously reported on several of these variants (see Methods for a list of variants and their
specifically-modified residues as well as Supplementary Table S1) using the deconstructed tobacco mosaic virus
(TMV)-based expression system in plants (Fig. 1a)24. This virus-assisted transient expression system exploits
plant viral vectors deconstructed for the rapid, industrial-scale expression of foreign proteins8, 9, 25. In developing this technology, we focused on a variant, pBChEV4 (A199S/F227A/S287G/A328W/Y332G) reported to
hydrolyze cocaine close to the upper limit set by substrate diffusion rates. Recently, another BChE variant with
a 6th mutation, P285A, was reported with further 2-fold better catalytic efficiency potentially bringing it to the
diffusion-limited maximal theoretical ceiling19.
The pBChEV4 was purified as previously reported for its WT counterpart8. SDS-PAGE analysis of pBChEV4
revealed that it resolved with an apparent molecular mass of ~65–70 kDa. This is similar to previously described
plant-derived BChE variants and slightly smaller than the ~85 kDa human BChE monomer, likely due to differences in glycosylation (Fig. 1b)8, 33. When highly-purified pBChEV4 was subjected to SEC-HPLC, about two thirds
was dimeric (Fig. 1c). Most of the remainder were monomers, but low amounts of tetramers were also detected
(Fig. 1c). Similar preparations of the WT enzyme, obtained through transient expression using the MagnICON
system, showed inverse proportions of monomers and dimers (Fig. 1c inset). Interestingly, stable expression of
WT enzyme in transgenic plants results in a substantial tetramer fraction8, 9.
The plant-derived pBChEV4 was examined closely for its ability to hydrolyze (−)-cocaine (Fig. 1d) and was
found to have >2000-fold improved catalytic efficiency against that substrate (kcat/KM = 1.9 × 109 M−1 min−1)
compared with the WT plant-derived enzyme (kcat/KM = 9.0 × 105 M−1 min−1). The higher efficiency is mostly
due to a large increase in kcat of pBChEV4 as compared to WT pBChE (5805 min−1 vs 2.6 min−1, respectively) with
nearly identical affinity to the substrate (KM = 3.0 µM vs KM = 2.9 µM, respectively). The catalytic efficiency of the
plant-derived variant and its improvement over WT BChE are in agreement with reports of this same variant
derived from other sources such as human embryonic kidney-293F cells34.
Cocaine hydrolase variants of BChE exhibit altered allosteric effects. The specific residues
changed on the road to BChE-based cocaine hydrolases included those at the bottom of the catalytic gorge
near the π-cation binding site (A328) and in the peripheral anionic site (Y332)13, 14. Catalytic activity against
(−)-cocaine was further improved through additional mutations to the oxyanion hole (A199)32, entrance to the
gorge (S287)15 and non-active site residues participating in H-bonding (F227)29. Together, these changes result
in increased catalytic efficiency against (−)-cocaine and potentially affect the enzyme’s interactions with other
substrates and ligands. Indeed, preliminary results with crude preparations revealed such effects (presented in
The XIth International Meeting on Cholinesterases, Kazan, Russia, June 4–9, 2012 “Plant-produced butyrylcholinesterase variants as versatile bioscavengers”). It was, therefore, of interest to determine if there were other such
allosteric effects on the function of several plant-derived BChE variants.
To rule out artifacts from our novel expression system, we first compared WT human plasma-derived
(hBChE) to pBChE. The Michaelis-Menten constant (KM) of WT hBChE and WT pBChE was determined with
the substrate, butyrylthiocholine. Nonlinear regression analysis showed values of 16.8 ± 2.9 μM and 14.6 ± 1.4 μM
respectively, similar to previous reports30 and essentially identical to each other (Figs 2 and 3, Table 1). WT hBChE
SCIEnTIfIC REPOrts | 7: 10419 | DOI:10.1038/s41598-017-10571-z
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Figure 1. Plant production and biochemical characterization of a cocaine hydrolase variant of BChE. (a) Plantbased strategy for the production of BChE. (i) Plant-expression optimized synthetic genes encoding human
BChE and variants thereof were cloned into the TMV-based MagnICON vector system, which recombines
in vivo to yield a cell-to-cell-spreading replicon. (ii) WT Nicotiana benthamiana plants were infiltrated
with agrobacteria harboring the MagnICON vectors (iii) and on peak accumulation day of the transientlyexpressed recombinant enzymes, leaf material was harvested, homogenized and the enzymes were purified.
Transient expression replicon: RpRd, RNA-dependent RNA polymerase; MP, movement protein gene; α,
barley alpha-amylase signal peptide. Wavy lines represent the translation products of the replicon genes.
(b) Purification of pBChEV4. Leaf extract from pBChEV4 –expressing plants was clarified by 70% (NH4)2SO4
precipitation then subject to ConA purification and eluted with stepwise increasing concentrations of methylα-D-mannopyranoside ([E1]-[E5]). Samples from these purification steps, protein size markers (M) and an
un-infiltrated WT N. benthamiana extract control (C) were subject to SDS-PAGE followed by silver-staining
(top) or BChE-specific immunoblotting (bottom). Lanes in respective gels were loaded based on equal
enzymatic activity. (c) Oligomerization of pBChEV4. Purified preparation of pBChEV4 was analyzed by SECHPLC; fractions were monitored for total protein content (top) and pooled fractions (0.5 mL every 1 min) for
enzymatic activity (bottom). Inset: fractionation pattern of WT pBChE. Molecular mass standards are indicated
with arrows. (d) Enzymatic hydrolysis of (−)-cocaine by WT pBChE and pBChEV4. Purified samples of WT
pBChE (green, 1.21 × 10−1 µM, upper and lower panel) and pBChEV4 (pink, 6.06 × 10−4 µM, upper panel).
Curves represent nonlinear regression fitted to the Michaelis-Menten model (Equation 1). Fitting the data to
the Radić model (substrate inhibition, Equation 2) does not result in a significantly better fit (based on the extra
sum-of-squares F test; p > 0.12 and p > 0.78 for the mutant and WT enzymes, respectively).

and WT pBChE also exhibited similar turnover numbers (kcat = 2.6 × 104 min−1 and kcat = 2.6 × 104 min−1, respectively) and catalytic efficiencies with the substrate analog butyrylthiocholine (BTC, kcat/KM = 1.6 × 109 M−1min−1
and kcat/KM = 1.8 × 109 M−1 min−1, respectively; Fig. 2, Table 1).
Catalytic efficiency of pBChEV2 (F227A/S287G/A328W/Y332A), pBChEV3 (A199S/S287G/A328W/Y332G),
and pBChEV4 (A199S/F227A/S287G/A328W/Y332G) toward BTC was reduced 100-, 37- and 5-fold, respectively,
mostly due to a large reduction in the turnover number but also to small changes in the KM. An even larger drop
SCIEnTIfIC REPOrts | 7: 10419 | DOI:10.1038/s41598-017-10571-z
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Figure 2. BTC hydrolysis by WT hBChE, WT pBChE, and pBChEV2-5. (a) Reaction rates are plotted against
substrate concentration (mean ± SEM). Plots in (b) zoom in on the low range of substrate concentrations. The
100% values and the goodness of fit values are as follows: WT hBChE, 100% = 1.57 ± 0.04 nmol/min, Equation
(2), R2 = 0.98; WT pBChE, 100% = 1.21 ± 0.07 nmol/min, Equation (2), R2 = 0.99; pBChEV2, 100% = 0.79 ± 0.10
nmol/min, Equation (3), R2 = 0.83; pBChEV3, 100% = 0.96 ± 0.01 nmol/min, Equation (3), R2 = 0.95; pBChEV4,
100% = 8.9 ± 0.6 nmol/min, Equation (3), R2 = 0.95; pBChEV5, 100% = 8.1 ± 0.3 nmol/min, Equation (3),
R2 = 0.95.

(~1000-fold) was observed in the catalytic efficiencies of pBChEV3 and pBChEV4 toward the substrate analog acetylthiocholine (ATC), but not in the case of pBChEV2, which dropped only 3-fold. Of note, the catalytic efficiency
of pBChEV5 (F227A/S287G/A328W/Y332G) toward both substrates remained equal to the WT enzyme (Table 1).
Human AChE and BChE exhibit characteristic allosteric effects due to low-affinity substrate binding at the
“peripheral site” (P-site) positioned near the entrance to the catalytic gorge35, 36. Despite the close homology
between the two cholinesterases, their substrates exert opposite allosteric effects. AChE is inhibited by ACh concentrations above 5 mM, but BChE is stimulated by similar concentrations of ACh and BCh and their thioester
analogues (ATC and BTC, Figs 2 and 3)30, 35, 37–41. This remains true regardless of the source of the enzyme, as
both WT hBChE and WT pBChE exhibited typical substrate activation against BTC and ATC (Figs 2 and 3,
Table 1)8. A simple modification of the Michaelis-Menten model (Equation 1) results in an adequate steady-state
description of the phenomena of substrate activation and inhibition in WT cholinesterases (Equation 2, Scheme
1 in Supplementary Fig. S1)39.
In striking contrast, hydrolysis of BTC by pBChEV3 and pBChEV4 revealed partial substrate inhibition (Fig. 2)
reminiscent of the kinetics of human AChE with ACh as was previously reported for native and plant-derived
human enzyme40, 41. But this inhibition (~40%) was much weaker than that exhibited by AChE (>90%), and their
respective peak activities were reached at BTC concentrations of approximately 70 µM and 230 µM respectively
(Fig. 2).
Even more complex enzymatic behavior was exhibited by pBChEV2 and pBChEV5, which differ from each
other only by, respectively, an alanine or a glycine residue at position 332 (Fig. 2). BTC at concentrations higher
than approximately 125 to 375 µM had more limited inhibitory effect on these variants (about 20%, Fig. 2) as
compared to pBChEV3 and pBChEV4. Interestingly, at still higher substrate concentrations (>2 mM) very slight
but highly reproducible substrate activation re-appeared (Fig. 2).
Hydrolysis of the smaller substrate ATC also revealed differences between the four variants. In all tested variants, ATC has much weaker inhibitory effect on its hydrolysis. In fact, pBChEV2 and pBChEV5, which were somewhat inhibited by high concentrations of BTC, were clearly activated by high ATC concentrations, as was the
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Figure 3. ATC hydrolysis by WT hBChE, WT pBChE, and pBChEV2-5. (a) Reaction rates are plotted against
substrate concentration (mean ± SEM). Plots in (b) zoom in on the low range of substrate concentrations. The
100% values and the goodness of fit values are as follows: WT hBChE, 100% = 0.97 ± 0.04 nmol/min, Equation
(2), R2 = 0.99; WT pBChE, 100% = 3.0 ± 0.1 nmol/min, Equation (2), R2 = 1.00; pBChEV2, 100% = 4.7 ± 0.1
nmol/min, Equation (2), R2 = 0.99; pBChEV3, 100% = 1.39 ± 0.00 nmol/min, Equation (3), R2 = 0.98; pBChEV4,
100% = 2.6 ± 0.1 nmol/min, Equation (1), R2 = 0.94; pBChEV5, 100% = 12.0 ± 0.7 nmol/min, Equation (3),
R2 = 0.99.

case of WT hBChE or WT pBChE (Fig. 3, Table 1). Still, pBChEV3 was inhibited at high concentrations of ATC
(but not to the extent that BTC provoked), while pBChEV4 was not allosterically affected by the smaller substrate,
exhibiting a hyperbolic Michaelis-Menten kinetic profile (Fig. 3).
Chen et al. found similar results regarding BTC for one of their cocaine hydrolyzing variants42. Their mutant,
hCocH, is a mammalian cell-derived equivalent of pBChEV4. They suggested that the change from substrate activation to substrate inhibition was due to destabilization of the rate-limiting step’s transition state when a second
substrate molecule binds in the peripheral site. This is plausible but remains speculative at this point.
The complex kinetic behavior of certain variants is reflected by the relatively poor fit between experimental
data and the standard model for BChE and AChE’s allosteric effects (Equation 2, Scheme 1 in Supplementary
Fig. S1). A closer look at hydrolysis rates at low BTC concentrations (Figs 2b and 3b) showed a sigmoidal pattern as BTC concentrations rise. Sigmoidal behavior is characteristic for homo-oligomeric enzymes that exhibit
cooperative binding of substrate molecules. Both BChE and AChE are oligomeric, tetramers and dimers being
most common in vivo. But the common view is that oligomerization status does not affect the enzymatic properties of either enzyme43–45. BChE purified from transgenic plants is about 50% tetrameric8, 9, while TMV-assisted
transient-expression in plants yields a mixture of monomers and dimers with few tetramers (Fig. 1c)46. As will be
explored further, it is possible that mutations introduced into BChE to improve its activity toward cocaine also
affected subunit interactions, which in turn made the enzyme behave cooperatively. Nonetheless, even monomeric enzymes with multiple substrate binding-sites, like all cholinesterases, can also exhibit cooperative (or
anticooperative) binding. We found that including Hill coefficients describing cooperativity (or anticooperativity)
into the standard analysis of uncompetitive inhibition, provides an adequate model to describe the behavior of
the BChE variants against BTC and ATC (Scheme 2 in Supplementary Fig. S1). While the molecular mechanism
is not yet established, the suggested model yields an estimate for factors that are assumed to be negligible for
the WT enzymes (Scheme 2 in Supplementary Fig. S1). Specifically, the model anticipates the possibility that
binding of one substrate molecule at either the peripheral or the active site may alter the binding of a second
molecule in the other site. The Hill coefficients (Table 1) demonstrate weak positive cooperativity, which would
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Substrate

BTC

ATC

WT hBChE

WT pBChE

pBChEV2

pBChEV3

pBChEV4

Kinetic behavior

Substrate activation

Substrate activation

Modified Hill

Modified Hill

Modified Hill

pBChEV5
Modified Hill

kcat/KM (M−1min−1)

1.6 × 109

1.8 × 109

1.8 × 107

4.9 × 107

3.4 × 107

3.2 × 108

kcat (min)

26241.2

25992.7

664.6

463.0

2806.0

27440.1

KM (µM)

16.8 ± 2.9

14.6 ± 1.4

37.1 ± 21.8

9.5 ± 3.2

83.0 ± 21.5

86.2 ± 27.7

Kss (mM)

2.2 ± 0.4

2.3 ± 0.3

0.4 ± 0.3

0.3 ± 0.1

0.4 ± 0.4

0.4 ± 0.2

ba

3.1 ± 0.2

2.5 ± 0.1

0.6 ± 0.2

0.3 ± 0.1

0.3 ± 0.2

0.7 ± 0.1

nb

n.a.

n.a.

1.1 ± 0.3

1.1 ± 0.2

2.8 ± 0.6

1.0 ± 0.2

xb

n.a.

n.a.

2.3 ± 2.0

2.3 ± 0.3

1.1 ± 0.6

1.5 ± 0.3

R2

0.98

0.99

0.83

0.95

0.95

0.95

Kinetic behavior

Substrate activation

Substrate activation

Substrate activation

Modified Hill

Michaelis-Menten

Modified Hill

kcat/KM (M−1min−1)

2.5 × 108

9.6 × 107

3.7 × 107

9.1 × 106

8.3 × 106

2.1 × 108

kcat (min)

9185.0

8490.1

3756.3

243.2

1093.3

16154.1

KM (µM)

36.7 ± 3.8

89.2 ± 7.8

101 ± 13

26.8 ± 4.8

132 ± 13

77.0 ± 4.5

Kss (mM)

2.3 ± 0.4

2.7 ± 0.5

2.4 ± 1.0

1.2 ± 0.4

n.a.

7.6 ± 3.3

b

2.2 ± 0.1

1.9 ± 0.1

1.6 ± 0.1

0.7 ± 0.1

n.a.

1.6 ± 0.3

n

n.a.

n.a.

n.a.

0.9 ± 0.1

n.a.

1.4 ± 0.1

x

n.a.

n.a.

n.a.

1.4 ± 0.5

n.a.

2.3 ± 1.1

R2

0.99

1.0

0.99

0.98

0.94

0.99

Table 1. Catalytic activity of WT BChE and cocaine hydrolase variants against butyrylthiocholine and
acetylthiocholine. aWhen b > 1, enzyme is exhibiting substrate activation; when b < 1, enzyme is exhibiting
substrate inhibition; if b = 1, the enzyme is following Michaelis-Menten kinetics. bn and x represent the Hill
coefficients. See Scheme 2 of Supplementary Fig S1 online and Equation 3. Positive cooperativity is observed
when either n > 1 or x > 1. Negative cooperativity is observed when n < 1 or x < 1.

Paraoxon

Iso-OMPA
−4.65 ± 0.03

Neostigmine
(0.8)**

−6.79 ± 0.02

BW284c51
(1)****

−3.86 ± 0.03

(2)****

WT hBChE

−8.04 ± 0.04

(0.9)

WT pBChE

−8.11 ± 0.03

(1)

−4.77 ± 0.03

(1)

−6.64 ± 0.01

(1)

−3.55 ± 0.05

(1)

pBChEV2

−9.69 ± 0.06

(38)****

−6.45 ± 0.05

(48)****

−7.75 ± 0.04

(13)****

−3.82 ± 0.11

(2)*

pBChEV3

−8.65 ± 0.07

(3)****

−4.45 ± 0.10

(0.5)***

−6.69 ± 0.05

(1)

−4.16 ± 0.10

(4)****

pBChEV4

−8.89 ± 0.05

(6)****

−4.87 ± 0.05

(1)

−6.81 ± 0.03

(1)****

−4.62 ± 0.09

(12)****

pBChEV5

−9.77 ± 0.05

(46)****

−6.39 ± 0.06

(42)****

−7.88 ± 0.03

(17)****

−3.31 ± 0.11

(1)*

Table 2. Inhibition of BTC hydrolysis activity. Log IC50 values ± SEM of various anticholinesterase inhibitors
versus WT hBChE, WT pBChE, and pBChEV2-5. Fold increase in sensitivity relative to WT pBChE is shown in
parentheses. Concentration of BChE variants was ~5 mU. *p < 0.05. **p < 0.01. ***p < 0.001. ****p < 0.0001.

be particularly important at low substrate concentrations. At higher substrate concentrations, effects on kcat are
more prominent and result in the observed substrate inhibition (against BTC) and activation (against ATC). A
non-equilibrium analysis of the interactions between the peripheral site and the active site, similar to the one
offered by Rosenberry47, should provide further insight into the mechanism involved here.

Inhibition analysis. The mutations rendering enzyme variants with the ability to efficiently hydrolyze
(−)-cocaine had profound allosteric effects on cholinesterase activity and our data suggest similar effects of those
mutations on sensitivities to various anticholinesterases. To test this possibility we studied representatives of
several important cholinesterase inhibitor classes including two OPs (paraoxon and Iso-OMPA), a carbamate
(neostigmine) and an AChE-specific bisquaternary inhibitor (BW284c51). To this end, BTC hydrolysis was analyzed following a 30-minute incubation with the inhibitors.
Compared to the WT enzyme (either plasma- or plant-derived), pBChEV2 and pBChEV5 had dramatically
increased sensitivity, reflected in decreased IC50 values. This was true for all tested anticholinesterase agents
except for the AChE-specific inhibitor BW284c51 (Fig. 4, Table 2). In fact, each of the variants were 40–50 fold
more sensitive to both OPs paraoxon and Iso-OMPA than the WT enzyme (p < 0.0001). In respect to neostigmine, the variants were also more sensitive than WT BChE but with smaller differences (10–20 fold). Similarly,
increased sensitivities were observed in an earlier plant-derived cocaine-hydrolyzing variant pBChEV1 (A328W/
Y332A) previously described by Geyer et al.25.
Higher-than WT sensitivities to paraoxon were also seen with pBChEV3 and pBChEV4 but the increase was not
as dramatic as in the other two variants (3–7 fold, Fig. 4, Table 2). The inhibition rate constants (ki) for inhibition
by paraoxon of WT pBChE and pBChEV4 were 3.14 × 106 and 1.7 × 107 M−1 min-1 respectively. On the other
hand, sensitivities to the other OP, iso-OMPA, and to neostigmine were near WT levels.
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Figure 4. Inhibition profiles of WT hBChE, WT pBChE and pBChEV2-5. Residual BTC hydrolytic activity
(mean ± SEM) with the indicated concentrations of paraoxon and Iso-OMPA (OP inhibitors), neostigmine
bromide (a carbamate inhibitor) and BW (an AChE-specific bis-quaternary inhibitor). The legends in each
panel list the traces in order of decreasing IC50. Plots of variants are compared to the human plasma-derived
enzyme. ns, no statistical difference; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Particularly interesting was the unexpected and small but statistically significant increase in sensitivity of
pBChEV3 and pBCHEV4 toward the AChE-specific bisquaternary inhibitor BW284c51 as compared to pBChE
(4- and 12-fold greater than WT, respectively). Thus, these variants have another AChE-like attribute besides
substrate inhibition. The inhibitor spans the length of the catalytic gorge, from the P-site at the surface of the
protein to the active site at the bottom of the gorge48. The only mutation common to both pBChEV3 and pBCHEV4
and absent from the other two variants is A199S. This alanine residue is conserved in both AChE and BChE and
is adjacent to the catalytic triad’s serine residue (S198). The equivalent position in AChE was not identified in previously published research as relevant for the interaction with BW284C51. The hydroxyl of the serine residue may
contribute a new H-bond to interact with the central carbonyl of BW284c51. However, without further data we
cannot rule out contributions to the increased sensitivity through direct and/or allosteric effects of other residue
changes in addition to the A199S mutation.
The substantially enhanced sensitivity of the cocaine hydrolases, especially pBChEV2 and pBChEV5 to the OP
poisons, has important potential implications for detoxifying these harmful substances. One approach to detoxification is to supply WT BChE to scavenge nerve agents. Another approach is to enhance BChE’s binding affinity
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Figure 5. % DCI profile of WT hBChE. The % DCI profiles for hBChE are color-coded in a cartoon diagram
from a spectrum of red-white-blue (red -highest, blue -lowest coupling to perturbation locations). (a) Upon
perturbation of catalytic residues (S198, E325, and H438 shown as grey sticks) the five mutation positions
(A199, F227, S287, A328, and Y332 shown as red sticks) shows high coupling (high % DCI values). (b) Upon
perturbation of five mutation positions (A199, F227, S287, A328, and Y332 shown as grey sticks) the catalytic
residues (S198, G325, and H438 shown as red sticks) shows high coupling (high % DCI values).

to anticholinesterase agents and create a more effective bioscavenger. Excitingly, though perhaps not surprising, mutations to BChE intended to enhance cocaine hydrolysis have altered the binding affinity of the cocaine
hydrolases toward anti-cholinesterase inhibitors. The enhanced scavenging for OP nerve agents by the cocaine
hydrolyzing variants suggests further development for dual use of the biologics.

Dynamic coupling index (DCI) analysis predicts allosteric coupling between the pentavalent
mutations of pBChEV4 and its active site. While all four variants exhibit novel enzymatic properties,

the superior efficiency of cocaine hydrolysis of pBChEV4 compared to other variants (Fig. 1d, unpublished data
and Zheng et al.16, 19), prompted further investigation of this variant. Specifically, we reasoned that the altered
substrate preference, hydrolysis kinetics, and inhibitor sensitivity suggest that the mutated positions in pBChEV4
(A199S/F227A/S287G/A328W/Y332G), all but one being quite distal to the active site, may be allosterically
linked to the catalytic locus. To test this hypothesis we used a recently developed metric, the “Dynamic Coupling
Index” (DCI)49 that identifies residues exhibiting significant fluctuation upon perturbation of functionally important loci including the active catalytic site and other substrate binding sites in the protein50.
Using DCI analysis, we identified positions that dynamically couple to residues of the catalytic triad, i.e. S198,
E325 and H438. According to this analysis, positions exhibiting high DCI values present residues that are dynamically linked to the active site despite being far away from the catalytic residues.
In Fig. 5a, the % DCI values for human BChE upon perturbation of the three catalytic residues are color-coded
within a spectrum of red-white-blue (from highest to lowest respectively). It appears that the five mutated positions of pBChEV4 variant (A199S, F227A, S287G, A328W and Y332G) are highly coupled to the catalytic triad.
Conversely, a reciprocal analysis of perturbing the five mutated positions and measuring % DCI values for other
residues show that the catalytic triad’s residues are highly coupled to these five mutated positions (Fig. 5b). This
reaffirms our hypothesis concerning dynamic interplay between these mutated positions and catalytic residues.
Moreover, the strong dynamic coupling between mutational sites and the catalytic site suggests that mutations
alter the conformational dynamics of the enzyme, leading to changes in enzymatic function.
The changes in catalytic properties of BChE variants can be partially attributed to the direct allosteric effect of
peripheral amino-acid substitution on the catalytic triad suggested by DCI analysis (Fig. 5). Our results also raise
the possibility that such mutations affect the interactions between enzyme subunits – specifically they may lead to
increased enzymatic cooperativity (Figs 2 and 3).

Dynamic flexibility index (DFI) analysis predicts global flexibility changes upon introduction
of mutations. To further substantiate our hypothesis and provide mechanistic insights on how these five

mutations lead to changes in enzymatic behavior, we explored the conformational dynamics of the WT and
the pBChEV4 variant using a dynamic flexibility index (DFI). DFI computes the fluctuation response of a given
position to the perturbations that occur at different parts of the protein using linear response theory, capturing the multi-dimensional effects when the protein structure is displaced out of equilibrium for example when
interacting with small molecules or other cellular constituents. DFI allows us to identify and map flexible and
rigid positions in the structure51, 52. DFI can be considered a measure of the local conformational entropy of a
given position within the set of interactions governed by the 3D fold of the protein due to its ability to probe the
conformational space of a protein at the residue level. For example, we recently used DFI to provide mechanistic
insights about emergence of new functions during the evolution of several protein families53, 54 and to explain the
molecular basis of single-nucleotide polymorphisms associated with genetic-diseases49, 52, 55.
We measured the DFI values of residues for WT hBChE and pBChEV4, and the % DFI profiles shows us the flexibility of the proteins in ranking order (Fig. 6a). Examining the flexibility of the monomer-monomer contact (binding) interfaces (Fig. 6b), it appears that the dimerization surface of pBChEV4 is less flexible in comparison with the WT counterpart.
Rigidified monomer-monomer interface is often associated with increased affinity56, 57. The association constant for
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Figure 6. % DFI profile of WT hBChE and pentavalent mutant. (a) The % DFI profiles of WT BChE (blue)
and BChEV4 (x-axis – residue numbers, y-axis – % DFI values at each position). (b) Color-coded structure
diagrams depicting the % DFI values at each position. The circled regions are part of the monomer-monomer
contact region (V377, D378, T457, K458, A459, I462, Y500, R509, M511, T512, K513, R514, L515). (c) The %
DFI profiles of monomeric (blue) and dimeric (green) WT BChE. (d) The % DFI profiles of monomeric (red)
and dimeric (purple) BChEV4. (e) Color-coded structure diagrams depicting the values of % DFI differences
between the dimeric forms of WT BChE and BChEV4 at each position. The red-white-blue code reveals loci with
increased flexibility (shades of red), decreased flexibility (shades of blue) or no change (white) in the mutant
dimer vs. the WT dimer.
dimerization depends on the entropic cost at the binding interface: dimerization causes the binding interface to be more rigid
and is therefore causing a decrease in entropy (negative entropy change associated with dimerization i.e. ΔSdimerization < 0).
Because the entropy level associated with the WT contact surface is higher than in the mutant (i.e., the former is more flexible
than the latter). Hence the entropic cost of dimerization is higher in WT than in the mutant (i.e. ΔSdimerization of WT is more
negative than that of the mutant). These results support our observation that preparations of pBChEV4 have higher proportion
of dimers as compared to pBChE, which is mostly monomeric.
The oligomerization of WT BChE is usually not regarded as affecting the enzymatic properties of the enzyme.
However, the sigmoidal nature of the enzyme kinetics observed here in the mutant variants (Figs 2 and 3) suggests
a degree of cooperativity. If this is the case we should see that dimerization induces new conformational dynamics
in the mutant but less so in the WT. To test this possibility, we explored how dimerization may affect the dynamics
of each monomeric subunit in WT and the mutant using DFI analysis. The five residue substitutions are introduced into the Elastic Network Model (ENM) model (see Methods) at the core of the DFI analysis as changes in
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the spring constants of the harmonic oscillators interconnecting the alpha-carbons of the adjoining amino-acids
(Supplementary Fig. S2). In other words, since the mutations introduced local destabilization around the mutational sites, we modeled this effect as decreased spring constants for the interactions of the mutational positions
(i.e. weakened harmonic interactions of the mutational sites).
With this approach, we can predict global changes in flexibility upon introduction of mutations. The local
disruption due to the mutations not only introduce enhanced flexibilities at the mutational sites, but can create
a global flexibility change in all positions (i.e. change in DFI profile) due to network of interactions. In fact,
it appears that the change in the flexibility of one region is compensated by the changes in flexibility of other
regions. As could be expected based on the well-documented lack of cooperativity in BChE upon its oligomerization, the DFI profile of the WT hBCHE subunit in monomeric and dimeric form are quite similar (Fig. 6c).
On the other hand, in the case of the BChEV4 mutant, the DFI profile of subunit in the dimer form differs notably
from that in monomeric form (Fig. 6d). This change suggests that dimerization induces new conformational
dynamics. Interestingly, when we map the localized differences in the % DFI values between mutant and WT, we
observed that the mutations lead to enhanced flexibility near the gorge site in the dimer, but less so in the monomer (Fig. 6e). The peripheral anionic site (D70, N68, Q119, A227), cation- π domain (W82, A328), acyl pocket
(L289 V288), and phenothiazine ring site (Y332, F329) exhibited increased flexibility upon mutations, while the
rigid profile of the catalytic triad (S198, E235, H438) did not change.
The DFI analysis suggests that compared to the WT, BChEV4 should have a better propensity to dimerize and
that within the mutant dimer there is an increase in flexibility near the gorge (Fig. 6e). We propose that changes
in flexibility might facilitate propagation of conformational changes from one subunit to the other. Thus, at low
substrate concentrations, binding of a substrate molecule on one of the subunits might positively affect substrate
binding and/or turnover at the catalytic gorge of the other subunit, explaining the sigmoidal kinetic observed at
low substrate concentrations (Figs 2b and 3b). At higher substrate concentrations, allosteric effects within each
subunit may lead to inhibition countering the cooperative enhancement and explaining the observed partial
substrate inhibition (Figs 2a and 3a). While speculative, this suggested mechanistic explanation raises several
predictions that will be tested by further experimentation and simulation including substrate docking.

Conclusions

The biochemical characterization of the plant-derived cocaine hydrolases reported here offers not only a better
understanding of a novel anti-cocaine treatment, but also possible protection from potent pesticides and other
anticholinesterase agents. The outcomes demonstrate the practicality and versatility of plant-derived recombinant
enzymes as potential multivalent biologics. As new mutations are being found to establish even more efficient
cocaine hydrolases, the results reported here point toward the importance of testing these enzymes for their
altered kinetic behavior toward their substrates and their potential as OP bioscavengers.

Methods

DNA constructs. Previously, we reported that the full-length human WT BChE gene (UniProt accession
number P06276) was optimized for expression in N. benthamiana plants (pBChE)8, 9. A synthetic gene encoding the A328W/Y332A mutant of pBChE14, 25, 58 (named here pBChEV1) was used as the template for successive
rounds of site-directed mutagenesis using the QuickChange method (Stratagene; mutagenic primers are listed in
Supplementary Table S2) yielding the following mutants: Variant 2 (pBChEV2): F227A/S287G/A328W/Y332A59,
Variant 3 (pBChEV3): A199S/S287G/A328W/Y332G15, Variant 4 (pBChEV4): A199S/F227A/S287G/A328W/
Y332G18, and Variant 5 (pBChEV5): F227A/S287G/A328W/Y332G (Brimijoin and co-workers, unpublished).
The mutated genes (also listed in Supplementary Table S1) were verified by DNA sequencing. A C-terminal
hexahistidine tag was added to the plant-expression optimized variants of BChE. The resulting constructs were
then cloned into a deconstructed tobacco mosaic virus (TMV)-based plant expression vector (MagnICON, kind
gift of Nomad Inc.) to be used in Agrobacterium tumefaciens-mediated transient expression in N. benthamiana.
Transient recombinant protein production in plants. An outline of the expression strategy is shown
in Fig. 1a. All expression vectors were electroporated into A. tumefaciens strain GV3101 electro-competent cells.
Transformed strains were screened via antibiotic selection as well as colony screen PCR and only positive colonies
were used for downstream studies. Bacteria cultures were grown at 30 °C until mid-logarithmic phase, pelleted
by centrifugation at 4,500 × g for 20 min at room temperature and then resuspended in infiltration buffer (10 mM
2-(N-morpholino)ethanesulfonic acid (MES), 10 mM magnesium sulfate heptahydrate, pH 5.5). Plants were
infected either by needle-less syringe injection or by whole-plant vacuum infiltration. Leaves infiltrated with each
variant were harvested at the respective day of peak expression as determined in previous reports24.
Enzymatic assays. To evaluate cocaine hydrolysis, a sensitive radiometric assay was used as previously
described60. Briefly, [3H](−)-cocaine labeled on the benzene ring (50 Ci/mmol), purchased from PerkinElmer
Life Sciences (Boston, MA), was used as a substrate with varying concentrations of (−)-cocaine. In the presence
of enzyme this reaction proceeded at room temperature (25°C) until stopped by the addition of 0.02 M HCl.
Any neutralized, liberated, labeled benzoic acid was then extracted with a toluene-based fluor and measured by
scintillation counting. On the other hand, the substrate would fractionate into the aqueous phase and would not
generate scintillation. Enzyme concentrations in the reaction mix were 800 ng/100 µL (1.21 × 10-1 µM) for WT
pBChE and 4 ng/100 µL (6.06 × 10−4 µM) for pBChEV4.
Choline ester hydrolysis activity was evaluated by a modified Ellman assay8, 61, 62. Activity was measured using
either butyrylthiocholine iodide (BTC, Sigma) or acetylthiocholine iodide (ATC, Sigma) at 30 °C in a Spectramax
190 spectrophotometer (Molecular Devices). Total soluble protein levels were determined by the Bradford protein assay (Bio-Rad Protein Assay Reagent, Bio-Rad)63. The assay was conducted in 96-well plate format over
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varying concentrations of BTC or ATC in final well volume of 200 μL. To account for product formed by substrate
self-hydrolysis, initial velocity of non-enzymatic hydrolysis was subtracted from initial velocity of the matched
enzyme-catalyzed reactions and reaction rates were then plotted as a function of substrate concentration.
Data were plotted using GraphPad Prism software, which was also used to fit the data by non-linear regression. The following models were fitted.
For Michaelis-Menten kinetics we used Equation (1).
For substrate inhibition/activation, we used Equation (2), following the model in Scheme 1 (Supplementary
Fig. S1), as was suggested by Radić and coworkers39.
The Radić model39 ascribes the allosteric effect of substrate binding at the peripheral binding site that causes
a change in the catalytic rate bkcat. When b > 1 we encounter substrate activation (WT BChE, see below), when
b < 1 we encounter substrate inhibition and when b = 1 we have a Michaelian enzyme (Equation 1). Kss is the
dissociation constant of the peripheral site.
Velocity vs substrate concentration data of some of the BChE variants described here fitted well to a model
initially suggested by LiCata and Allewell64 for aspartate transcarbamylase (Scheme 2 in Supplementary Fig. S1).
This model describes the reaction in terms of uncompetitive substrate inhibition/activation and cooperative substrate binding with characteristic Hill coefficients. The equation describing this model is Equation (3).
The Hill coefficients n and x need not be integers. Values greater than one describe cooperativity, while values
of less than one describe anti-cooperativity. The parameters b and Kss function in the same way as in Equation (2).
 V [S ] 

v =  max
 K + [S] 
M

(1)

 1 + b[S]/Kss 

Vmax


v = 
 1 + [S]/K  1 + K /[S] 
ss
M

(2)

v=

Vmax(1 + b[S]x /Kssx )
n
1 + (K M
/[S]n ) + ([S]x /Kssx )

(3)

Inhibition. Inhibition studies were conducted with the OPs paraoxon (diethyl (4-nitrophenyl) phosphate) and

iso-OMPA (N- [bis(propan-2-ylamino)phosphoryloxy-(propan-2-ylamino)phosphoryl]propan-2-amine), the carbamate neostigmine bromide ([3-(dimethylcarbamoyloxy)phenyl]-trimethylazanium;bromide), or the reversible
bisquaternary inhibitor BW284c51 (BW, [4-[5-[4-[dimethyl(prop-2-enyl)azaniumyl]phenyl]-3-oxopentyl]phenyl]
-dimethyl-prop-2-enylazanium;dibromide). The four inhibitors were purchased from Sigma (St Louis, MO).
Preparations of BChE and variants thereof were incubated in 96-well plate format with indicated concentrations of the inhibitors for 30 min at room temperature followed by activity measurements based on modified
Ellman assay using 1 mM BTC as the substrate. IC50 values were determined by non-linear regression (GraphPad
Prism) fit according to Equation (4).
The inhibition rate constant (ki) of pBChEV4 treated with paraoxon was determined as previously described65.
Inhibition curves were statistically analyzed by the extra sum-of-squares F test (GraphPad Prism) together
and were found to be significantly different from each other. Following up with individual comparisons to WT
pBChE revealed statistical significance in all except the following: paraoxon inhibition of WT pBChE vs WT
hBChE, Iso-OMPA inhibition of WT pBChE vs pBChEV4, and neostigmine inhibition of WT pBChE vs pBChEV3.
residual BChE activity =

100

(log [I] − logIC50)

1 + 10

(4)

Dynamic Flexibility Index (DFI) analysis.

Dynamic flexibility index (DFI) metric51 is based on the
Perturbation Response Scanning method (PRS) that couples covariance matrix of residue displacement with
linear response theory (LRT)49, 66, 67.
PRS was originally based on the Elastic Network Model (ENM). In ENM, protein is viewed as an elastic
network, in which each amino acid is represented by C-alpha position, and a harmonic interaction is assigned
to pairs of amino-acids within a specified cutoff distance67. Simply put, in the WT BChE, two residues that are
interacting with each other are represented by a harmonic interaction with the same spring constant (lower left in
Supplementary Fig. S2). In contrast, a mutation at a given position is considered to destabilize the interactions of
the mutational site. Thus, this destabilization is introduced in the ENM as a decrease in spring constant providing
a loss in interaction strength with mutated positions (lower right in Supplementary Fig. S2), the mutation positions S199, A227, G287, W328, and G332 are shown as red spheres).
In PRS, we apply a random Brownian kick as a perturbation to a single residue in the chain one at a time,
sequentially. This perturbation mimics the external forces exerted on the protein through interactions with
another protein, another biological macromolecule or small molecule ligand, in silico. The perturbation cascades through the residue interaction network and may introduce conformational changes in the protein. Then,
we compute the response fluctuation profile of all other residues to the perturbation as linear response using
Equation (5) where F is a unit random force on selected residues, H−1 is the inverse of the Hessian matrix and ΔR
is the positional displacements of the N residues of the protein in three dimensions50, 51, 66–68.
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The response fluctuation profile is used to calculate the DFI scores using Equation (6), where ⌈∆R j ⌉i is the
response fluctuation amplitude of position i, upon perturbing position j. Thus, the DFI of position i is the total
fluctuation response of position i upon perturbing all positions in the chain one at a time. The DFI value for each
position is normalized to the overall intrinsic flexibility of the protein chain. High and low DFI scores could be
interpreted as dynamically flexible sites and rigid (hinge) sites, respectively55. The DFI scores can be converted
into percentile ranking scores, namely % DFI.
1
[∆R]3Nx1 = [H ]−
3Nx 3N [F]3Nx1

DFIi =

(5)

j
∑ Nj =1⌈∆R ⌉i

j
∑ iN=1∑ Nj =1⌈∆R ⌉i

(6)

Dynamic Coupling Index (DCI) Analysis. The position-specific metric DCI uses PRS methodology
to identify the residues that are allosterically linked to functionally critical positions through residue fluctuation dynamics for a given protein. The index DCI computes whether this position exhibits a higher fluctuation
response to a perturbation that occurred at functionally critical sites (e.g. binding sites or catalytic site) compared
to the perturbations at the other sites of the chain. It is measured as the ratio of average fluctuation responses of a
given residue j upon perturbations of functionally critical sites to the average response of residue j upon perturbations placed on all other residues using
DCIi =

∆R j i /Nfunctional
∑ Nj =functional
Nfunctional
j
∑ iN=1∑ Nj =1 ∆R i /N

(7)

In Equation (7), ∆R j i is the response fluctuation profile of residue j upon perturbation of residue i. The
numerator is the average mean square fluctuation response obtained over the perturbation of the functionally
critical residues Nfunctional; the denominator is the average mean square fluctuation response over all residues49, 50.
These DCI profiles can also be converted into rank profiles, which are labeled as % DCI profiles. The positions
that have higher % DCI values are functionally important residues that are not linked to the functional residues by
direct covalent bonds or non-covalent interactions (e.g. hydrogen bonding and van der Waals interactions), but
are allosterically communicating over longer distances (i.e. allosteric dynamic coupling) via residues that form
extensive interaction networks.

Purification. All extraction and purification procedures were carried out at 4 °C. Large-scale protein preparations were extracted from plant leaf tissue by blending in the presence of 50 mM sodium phosphate, 150 mM
sodium metabisulfite, 1 mM EDTA, pH 8.0. Extract was filtered through double-layer miracloth and centrifuged
at 22,000 × g for 30 min followed by pH adjustment to pH 5.0 and further clarification by ammonium sulfate precipitation. The pellet was resuspended in cold 1X phosphate buffered saline (PBS) and dialyzed overnight against
1X PBS, pH 7.4 to remove salts and sodium metabisulfite. The clarified protein preparation was then subjected
to sequential affinity chromatography steps with Concanavalin-A-Sepharose followed by procainamide affinity
chromatography as previously described8.
SDS-PAGE and western blot. Plant-derived protein preparations were resolved by SDS-PAGE on 8% poly-

acrylamide gels followed by staining with Pierce Silver Stain Kit (Thermoscientific). In parallel, protein was transferred to nitrocellulose membrane and decorated with rabbit polyclonal anti-hBChE antibodies (kindly provided by
Dr. Oksana Lockridge) and anti-rabbit IgG-Horse Radish Peroxidase secondary antibodies (Santa Cruz Biotechnology)
followed by chemiluminescence analysis using western blotting luminol reagent (Santa Cruz Biotechnology).

Size exclusion HPLC. SEC-HPLC fractionation of purified preparations of pBChEV4 was carried out as previously described using Alliance HPLC (Waters) with a Shodex KW-803 column (8 × 300 mm, Kawasaki)8. All
samples were run in filtered, degassed mobile phase buffer (20 mM Na2HPO4/NaH2PO4, pH 8.0, 200 mM NaCl,
0.04% NaN3) at a flow rate of 0.5 mL/min. Molecular mass standards used were blue dextran (2000 kDa) and the
proteins β-amylase (200 kDa), bovine serum albumin (66 kDa) and carbonic anhydrase (29 kDa). Fractions were
collected and analyzed for cholinesterase activity by the modified Ellman assay.
Data availability statement.

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files) except for the raw computational datasets that are available from the corresponding author on reasonable request.
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